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Abstract: Hepatocellular carcinoma (HCC) is a slowly developing
malignancy postulated to evolve from premalignant lesions in
chronically damaged livers. However, it was never established that
premalignant lesions actually contain tumor progenitors that give
rise to cancer. Here, we describe the isolation and characterization
of HCC progenitor cells (HcPCs) from different mouse HCC models.
Unlike fully malignant HCC, HcPCs give rise to cancer only when
introduced into a liver undergoing chronic damage and compensa-
tory proliferation. Although HcPCs exhibit a similar transcriptomic
proﬁle to bipotential hepatobiliary progenitors, the latter do not give
rise to tumors. Cells resembling HcPCs reside within dysplastic
lesions that appear several months before HCC nodules. Unlike early
hepatocarcinogenesis, which depends on paracrine IL-6 production
by inﬂammatory cells, due to upregulation of LIN28 expression,
HcPCs had acquired autocrine IL-6 signaling that stimulates their
in vivo growth and malignant progression. This may be a general
mechanism that drives other IL-6-producing malignancies.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver.
Hepatocellular carcinoma (HCC) is the ﬁfth and seventh most
common cancer in men and women in the world, respectively
[1]. The diverse etiology of HCC includes hepatitis B virus (HBV)
and hepatitis C virus (HCV) infection, alcoholic disease, and obes-
ity. These diverse factors often lead to cirrhosis, which is present
in more than 80 to 90% of HCC patients [1]. Moreover, these fac-
tors contribute to tumor heterogeneity and play a signiﬁcant role
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E-mail address: xw3u@nih.gov (X.W. Wang).in the development of HCC, making current systemic therapies
unsatisfactory. Current studies suggest that HCC can be derived
from cancer stem cells (CSCs), which can contribute to tumor het-
erogeneity and chemoresistance. However, the origins of CSCs are
still debatable. In a study by He and colleagues, the authors
provide evidence for the existence of hepatic cancer progenitor
cells (HcPCs) in preneoplastic regions of foci altered hepatocytes
(FAH), which have cancer stem cell-like characteristics. Interest-
ingly, the authors demonstrate that there are multiple cell types
that reside within the FAH, including CD44+ CSCs, suggesting that
the FAH may serve as a niche for CSC proliferation.
In liver cancer, early observations of highly proliferative pre-
neoplastic nodules or FAH in chemical hepatocarcinogenesis
rodent models suggested that HCC arose from mature hepato-
cytes [2]. Moreover, similar lesions are frequently observed in
human HCC samples [3]. However, current studies indicate that
HCC can also arise from adult liver progenitor cells or liver CSCs
[2]. CSCs are neoplastic cells that possess distinct survival mech-
anisms and stem cell properties that are crucial for the mainte-
nance and propagation of the tumor. Although the origins of
CSCs are not well established, CSCs are hypothesized to originate
from tumor progenitor cells, stem cells, or dedifferentiated cells
that have acquired CSC characteristics. Notably, recent studies
in mice revealed that any cell type in the hepatic lineage can
undergo oncogenic reprogramming into a CSC [4]. The study by
He and colleagues in Cell demonstrates that IL-6 signaling is
required for promoting HcPCs tumorigenicity (Fig. 1).
The role of preneoplastic lesions in HCC is debatable. FAH con-
sists of highly proliferative cells compared to the parenchyma.
Although these preneoplastic regions are predictive of HCC and
are frequently found in cirrhotic livers, the overall histology does
not indicate HCC, but rather, compensatory proliferation induced
by cirrhosis [3,7]. According to He and colleagues, FAH consists of
aggregates of diverse HcPCs with elevated expression of various
markers including CD44, EpCAM, and alpha-feto protein (AFP).
Interestingly, the authors demonstrate that diethyl nitrosamine
(DEN)-induced HcPCs have a similar transcriptome as HCC cells
and bipotential progenitor cells. While there are similarities
between progenitor cells and HcPCs, the authors further elegantly
show that only HcPCs are tumorigenic in damaged livers (i.e.,
chronic injury and compensatory proliferation) through IL-6
autocrine signaling. Finally, He and colleagues show that IL-6 is
required for the progression of HcPCs to HCC, however, the
ablation of IL-6 does not completely inhibit tumor progression,
suggesting that other factors such as CSF1 or TGFbmay be at play
[8,9]. This study, as with others, is pivotal in providing evidence14 vol. 60 j 1304–1305
Fig. 1. The impact of the liver milieu on preneoplastic lesions. Within the cirrhotic liver are foci of altered hepatocytes (FAH) that harbors multiple hepatic cell lineages
including aggregates of hepatic cancer progenitor cells (HcPCs). The damaged liver provides a microenvironment that is conducive for tumor progression, which allows
HcPCs to become cancer stem cells (CSCs).
JOURNAL OF HEPATOLOGYof how the microenvironment, such as cirrhosis of the liver,
affects tumorigenesis by providing a perfect niche for cellular
proliferation.
Currently, there is little evidence that CSCs are found within
the FAH in humans, however, He’s study supports the novel
model that HcPCs may be precursors of CSCs and that FAH can
shelter CSCs. As discussed by He and colleagues, the heteroge-
neous expression of stem cell markers within the HcPC aggre-
gates suggest that they are composed of more than one cell
type including oval cells, normal hepatocytes, and differentiated
progenitors cells. A subgroup of these cells may be different from
CSCs in that they require the right milieu to become malignant;
whereas CSCs are tumorigenic and can maintain and propagate
tumors. Furthermore, FAH is also composed of multiple cell types,
such as stromal and immune cells; all of which can provide a dis-
tinct microenvironment that is conducive to the regulation of
stemness and proliferation of CSCs.
Interestingly, only 5–7% of cirrhotic patients will develop HCC
and most cirrhotic tissues contain FAHs [1]. This leads to the
question as to whether FAHs of cirrhotic tissues from non-HCC
patients also contain HcPCs. If so, why are they not tumorigenic?
Is this tumorigenicity strictly due to the elevated levels of IL-6 or
other cytokines necessary to induce the stemness properties nec-
essary for tumor growth? The answer to these questions would
enhance the understanding of how the microenvironment plays
a role in tumor development. Furthermore, the observation that
autocrine IL-6 signaling is important for the transformation of
HcPCs suggests that IL-6 can be a candidate biomarker for early
HCC detection. Moreover, elevated serum IL-6 levels are found
in HCC and have been associated with metastatic HCC [5]. In fact,
studies have suggested that IL-6 may be more sensitive in identi-
fying HCC than AFP, the most commonly used biomarker for HCC
detection [6]. However, IL-6 plays two signiﬁcant roles in the
liver, (A) as a pro-inﬂammatory cytokine produced by Kupffer
cells during acute phase response and (B) as a tumor promoter
in damaged liver. Because of IL-6’s dual role, at what point doesJournal of Hepatology 2014IL-6 become a tumor promoter? Understanding the underlying
role of IL-6 during the progression of HCC may shed light on
the appropriate stage of hepatocarcinogenesis at which IL-6
may be a prognostic HCC marker. While many questions remain,
this study provides insight into the origin of HCCs and enhances
our understanding of the microenvironment’s role in tumor
development.Conﬂict of interest
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